Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burt Nabors

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Central nervous system cancers, version 2.2014. Featured updates to the NCCN GuidelinesLouis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
International Journal of Cancer|April 10, 2019
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and HispanicsQuinn T Ostrom, Kathleen M Egan, L Burt Nabors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017Louis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Central Nervous System Cancers, Version 1.2015Louis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyLouis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Central nervous system cancers, version 2.2014. Featured updates to the NCCN GuidelinesLouis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
International Journal of Cancer|April 10, 2019
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and HispanicsQuinn T Ostrom, Kathleen M Egan, L Burt Nabors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017Louis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Central Nervous System Cancers, Version 1.2015Louis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyLouis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Pageof 14